16.40
+0.23
+(1.40%)
At close: April 17 at 8:20:04 AM GMT+2
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 3 | 3 |
Avg. Estimate | 12.99B | 13.25B | 52.85B | 54.43B |
Low Estimate | 12.73B | 13.25B | 49.78B | 49.71B |
High Estimate | 13.25B | 13.25B | 55.14B | 59.67B |
Year Ago Sales | 11.99B | 12.93B | 50.07B | 52.85B |
Sales Growth (year/est) | 8.30% | 2.45% | 5.55% | 2.99% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
PG81.F | -- | -- | -- | -- |
S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
Maintains | Barclays: Underweight to Underweight | 4/10/2025 |
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 3/25/2025 |
Maintains | Raymond James: Strong Buy to Strong Buy | 1/28/2025 |
Maintains | Barclays: Underweight to Underweight | 1/16/2025 |
Upgrade | Wolfe Research: Peer Perform to Outperform | 1/10/2025 |
Downgrade | Wells Fargo: Overweight to Equal-Weight | 12/18/2024 |